EGFR and non-small cell lung carcinoma: Approximately 1.8 million new lung cancer cases were diagnosed in 2012.1,2 Current recommendations support epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) to treat the advanced non-small cell lung cancer (NSCLC) with EGFR-mutation.